A (Dollar) 350-million deal has been finalized between British pharmaceuticals giant GlaxoSmithKline and Adaptimmune to help develop and sell the biotechnology firm's cancer drugs, the companies said on Monday. Adaptimmune announced in a statement that it has entered a "strategic cancer immunotherapy collaboration" with GSK to "develop and commercialise novel cell-based therapies" in its lead clinical cancer programme. The biotech firm, which is based in Oxford, ...
Read More
You have just read an article categorized health
titled Biotech Specialist and Glaxo Finalize a (Dollar) 350 Cancer Deal.
Written by:
editor -
Tuesday, June 3, 2014
There are currently no comments for "Biotech Specialist and Glaxo Finalize a (Dollar) 350 Cancer Deal"
Post a Comment